2.62
price down icon1.87%   -0.05
 
loading
Immunitybio Inc stock is traded at $2.62, with a volume of 7.82M. It is down -1.87% in the last 24 hours and down -46.26% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$2.67
Open:
$2.66
24h Volume:
7.82M
Relative Volume:
1.30
Market Cap:
$1.91B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.2982
EPS:
-1.14
Net Cash Flow:
$-425.62M
1W Performance:
-8.71%
1M Performance:
-46.26%
6M Performance:
-59.69%
1Y Performance:
-42.16%
1-Day Range:
Value
$2.61
$2.7065
1-Week Range:
Value
$2.61
$3.18
52-Week Range:
Value
$2.61
$10.53

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
672
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.62 1.91B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
Dec 20, 2024

D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat

Dec 19, 2024
pulisher
Dec 17, 2024

ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha

Dec 16, 2024
pulisher
Dec 15, 2024

ImmunityBio Shares Plunge After Share Offering - Los Angeles Business Journal

Dec 15, 2024
pulisher
Dec 14, 2024

ImmunityBio (NASDAQ:IBRX) Hits New 52-Week LowShould You Sell? - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

ImmunityBio: Despite Share Price & Funding Woes Muddy Path To Long-Term Success (IBRX) - Seeking Alpha

Dec 13, 2024
pulisher
Dec 12, 2024

ImmunityBio stock plummets on announcing common stock offering - MSN

Dec 12, 2024
pulisher
Dec 12, 2024

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering - Yahoo Finance

Dec 12, 2024
pulisher
Dec 12, 2024

Form 424B5 ImmunityBio, Inc. - StreetInsider.com

Dec 12, 2024
pulisher
Dec 12, 2024

SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow

Dec 12, 2024
pulisher
Dec 11, 2024

ImmunityBio announces proposed public offering of common stock - MSN

Dec 11, 2024
pulisher
Dec 11, 2024

ImmunityBio’s Cash Burn And Dilution Dampen Anktiva’s Potential (NASDAQ:IBRX) - Seeking Alpha

Dec 11, 2024
pulisher
Dec 11, 2024

ImmunityBio Shares Slide 33% After Public Offering Prices - MarketWatch

Dec 11, 2024
pulisher
Dec 11, 2024

What's Going On With ImmunityBio Shares Wednesday? - Benzinga

Dec 11, 2024
pulisher
Dec 11, 2024

IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc.IBRX - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire

Dec 11, 2024
pulisher
Dec 11, 2024

ImmunityBio Shares Down on Plans for Public Offering - MarketWatch

Dec 11, 2024
pulisher
Dec 11, 2024

ImmunityBio plans public stock offering By Investing.com - Investing.com Canada

Dec 11, 2024
pulisher
Dec 10, 2024

ImmunityBio plans public stock offering - Investing.com India

Dec 10, 2024
pulisher
Dec 10, 2024

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock - Business Wire

Dec 10, 2024
pulisher
Dec 07, 2024

Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN

Dec 07, 2024
pulisher
Dec 07, 2024

More layoffs for ImmunityBio's Dunkirk facility - MSN

Dec 07, 2024
pulisher
Dec 07, 2024

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - The Eastern Progress Online

Dec 07, 2024
pulisher
Nov 30, 2024

(IBRX) Investment Analysis - Stock Traders Daily

Nov 30, 2024
pulisher
Nov 25, 2024

ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Nov 25, 2024
pulisher
Nov 23, 2024

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey

Nov 23, 2024
pulisher
Nov 22, 2024

ImmunityBio and nCartes partner to automate clinical trial data processes - Clinical Trials Arena

Nov 22, 2024
pulisher
Nov 22, 2024

Town hopeful after ImmunityBio tour - Evening Observer

Nov 22, 2024
pulisher
Nov 22, 2024

Town Hopeful After ImmunityBio Tour - Jamestown Post Journal

Nov 22, 2024
pulisher
Nov 21, 2024

ImmunityBio partners with nCartes to streamline trials - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

ImmunityBio and nCartes Enter Collaboration Agreement on Clinica - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

ImmunityBio, nCartes announce collaboration on clinical trial data fulfillment - TipRanks

Nov 21, 2024
pulisher
Nov 21, 2024

ImmunityBio partners with nCartes to streamline trials By Investing.com - Investing.com UK

Nov 21, 2024
pulisher
Nov 21, 2024

ImmunityBio Partners with nCartes to Revolutionize Clinical Trial Data Management | IBRX Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 20, 2024

Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria

Nov 20, 2024
pulisher
Nov 20, 2024

ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace

Nov 19, 2024
pulisher
Nov 19, 2024

ImmunityBio announces new data from QUILT 3.032 study - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

ImmunityBio's Bladder Cancer Drug Shows 71% Response Rate in Key Trial | IBRX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 14, 2024

Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St

Nov 14, 2024
pulisher
Nov 13, 2024

ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

ImmunityBio Inc (IBRX) Q3 2024 Earnings: GAAP EPS of -$0.12, Rev - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

ImmunityBio: Q3 Earnings Snapshot - The Pioneer

Nov 12, 2024
pulisher
Nov 12, 2024

ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations

Nov 12, 2024
pulisher
Nov 12, 2024

ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immunitybio Inc Stock (IBRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Adcock Richard
CEO & President
Feb 05 '24
Option Exercise
0.00
83,334
0
286,303
Simon Barry J.
Director
Jan 31 '24
Option Exercise
0.00
57,200
0
3,145,855
Sachs David C.
Chief Financial Officer
Jan 31 '24
Option Exercise
0.00
70,745
0
212,673
LAUER REGAN J
Chief Accounting Officer
Jan 31 '24
Option Exercise
0.00
32,872
0
107,804
Sachs David C.
Chief Financial Officer
Dec 31 '23
Option Exercise
0.00
30,397
0
152,439
Adcock Richard
CEO & President
Dec 31 '23
Option Exercise
0.00
34,483
0
220,065
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):